# COMparison Between All immunoTherapies for Multiple Sclerosis.

> **NCT03193866** · — · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 3526 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03193866
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-02
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 3526 (ACTUAL)
- **Last updated:** 2025-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193866, "COMparison Between All immunoTherapies for Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03193866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*